About the Ypsomed Group
Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 35 years’ experience. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brands mylife Diabetescare directly to patients or via pharmacies and hospitals as well as under YDS Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs over 2 200 employees.
Ypsomed Diabetes Care
With its mylife Diabetescare brand, Ypsomed operates successfully in the B2C business with products and services for people with diabetes mellitus. The product portfolio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed’s subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).
Diabetes: A global disease with pandemic growth predicted in the coming 20 years. Currently diabetes is growing at approximately 9 % p. a.
Ypsomed Delivery Systems
Our pharmaceutical and biotech customers purchase injection systems and corresponding services under the YDS brand, Ypsomed Delivery Systems. They do this via the industry leader, as Ypsomed is the world’s largest developer and manufacturer of pens and autoinjectors with which patients can administer their liquid medication subcutaneously themselves.
Trends for future drugs: Drugs are becoming more specific, e.g. in the treatment of autoimmune diseases. Instead of a generic drug (e.g. Humira®), a large number of new, very specific drugs come onto the market. New drugs for Alzheimer's disease, obesity and rare diseases are being developed. Cancer drugs are also becoming more specific. Efforts to develop active ingredients for subcutaneous injection open up opportunities for self-medication with auto- and patch injectors.
Sales and EBIT at group level
